The Plasmodium berghei sexual stage antigen PSOP12 induces anti-malarial transmission blocking immunity both in vivo and in vitro  by Sala, K.A. et al.
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Anti-malarial  transmission-blocking  vaccines  (TBVs)  aim  to inhibit  the transmission  of  Plasmodium  from
humans to mosquitoes  by targeting  the  sexual/ookinete  stages  of the parasite.  Successful  use  of  such
interventions  will  subsequently  result  in  reduced  cases  of  malarial  infection  within  a human  population,
leading  to local  elimination.  There  are  currently  only  ﬁve  lead  TBV  candidates  under  examination.  There
is  a consequent  need  to  identify  novel  antigens  to  allow  the formulation  of  new  potent  TBVs.  Here  we
describe  the design  and  evaluation  of  a potential  TBV  (BDES-PbPSOP12)  targeting  Plasmodium  berghei
PSOP12  based  on the baculovirus  dual  expression  system  (BDES),  enabling  expression  of antigens  on  the
surface  of viral  particles  and  within  infected  mammalian  cells.  In silico  studies  have  previously  suggested
that  PSOP12  (Putative  Secreted  Ookinete  Protein  12)  is expressed  within  the  sexual  stages  of  the parasite
(gametocytes,  gametes  and  ookinetes),  and  is a member  of  the  previously  characterized  6-Cys  family  of
plasmodial  proteins.  We  demonstrate  that PSOP12  is  expressed  within  the sexual/ookinete  forms  of the
parasite,  and  that  sera  obtained  from  mice  immunized  with  BDES-PbPSOP12  can  recognize  the  surface
of  the  male  and female  gametes,  and  the ookinete  stages  of the  parasite.  Immunization  of  mice  with
BDES-PbPSOP12  confers  modest  but  signiﬁcant  transmission-blocking  activity  in  vivo  by  active  immu-
nization  (53.1%  reduction  in  oocyst  intensity,  10.9% reduction  in oocyst  prevalence).  Further  assessment
of  transmission-blocking  potency  ex  vivo  shows  a dose-dependent  response,  with  up  to a 76.4%  reduction
in  intensity  and  a  47.2%  reduction  in  prevalence  observed.  Our  data  indicates  that  PSOP12  in  Plasmodium
spp.  could  be a potential  new  TBV  target  candidate,  and  that  further  experimentation  to  examine  the
protein  within  human  malaria  parasites  would  be  logical.
©  2014  The  Authors.  Published  by  Elsevier  Ltd. This  is an  open  access  article  under  the CC  BY-NC-ND
license  (http://creativecommons.org/licenses/by-nc-nd/3.0/).. Introduction
Malaria is a global disease of man  caused by parasites of the
enus Plasmodium, which are transmitted exclusively by Anopheles
osquitoes. Global morbidity and mortality have been substan-
ially reduced over recent years [1], due to the use of interventions
uch as long-lasting insecticidal nets and increased access to care.
espite this, there are currently an estimated 219 million human
ases annually, causing 627,000 deaths per year, with the majority
∗ Corresponding author. Tel.: +44 0 207594 5350.
E-mail address: andrew.blagborough@imperial.ac.uk (A.M. Blagborough).
1 Contributed equally.
ttp://dx.doi.org/10.1016/j.vaccine.2014.11.038
264-410X/© 2014 The Authors. Published by Elsevier Ltd. This is an open access article unof disease burden in African children under the age of 5 [1]. The
tools currently available to combat the disease are insufﬁcient to
interrupt transmission in areas of higher endemicity [2] and there
remains growing concern about the spread of insecticide and par-
asite drug resistance [3].
It is now widely agreed that to achieve eradication, it is neces-
sary to use interventions that inhibit the transmission of parasites
from humans to mosquitoes. Successful use of such interventions,
either alone, or in combination with other anti-malarial measures,
will subsequently result in reduced cases of malarial infection
within an endemic population leading to local elimination. A poten-
tial manner of achieving this is by targeting Plasmodium using
transmission-blocking vaccines (TBVs) against the sexual stages of
the parasite. TBVs have a number of unique biological advantages
der the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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ver vaccines targeting other stages of the Plasmodium lifecy-
le; these include low numbers of the target parasite stages, a
omparatively long vulnerable extracellular period, and reduced
ntigenic polymorphism [4]. It has been previously demonstrated
n numerous studies that transmission-blocking antibodies can
uccessfully inhibit transmission from vertebrate to mosquito. Both
ertilization and ookinete formation within the midgut can be
nhibited by the presence of vaccine-induced antibodies within
he mosquito blood meal. Fertilization can be blocked through
gglutination, steric hindrance, or complement-mediated lysis of
ametes [5,6], whereas ookinete development can be inhibited
r fully prevented by complement-mediated lysis, melanization,
ntibody-dependent phagocytosis or by blocking recognition of
he midgut epithelial cells [7,8]. In the laboratory transmission-
locking antibodies can result in profound and often total reduction
 in parasite transmission to the mosquito vector.
A wide range of different immunogenic targets that potentially
nduce transmission-blocking activity in Plasmodium have been
nvestigated over the last three decades. Five parasite-derived pro-
eins are currently considered to be lead TBV candidates; P25 and
28 (both expressed on the surface of zygotes and ookinetes),
48/45, P230 and HAP2. P48/45 is expressed by gametocytes and is
resent on the surface of male gametes [9,10]. The protein plays a
ey role in parasite fertilization, and targeted disruption of the gene
ffects the male gamete’s ability to attach to female gametes. [11].
nti-P48/45 antibodies are found in human serum from endemic
reas, and their abundance correlates with transmission-blocking
ctivity [12–14]. Transmission-blocking induced by recombinant
rotein-derived P48/45 antibodies is signiﬁcantly dependent on
he recognition of conformation-dependent epitopes [15]. P230,
lso present on the surface of the gamete, is a promising TB
mmunogen. Antibodies against P230 inhibit or prevent oocyst
evelopment [16,17], and have been demonstrated to lyse gametes
n a complement-dependent manner. Previous studies have sug-
ested that P48/45 and P230 form a complex at the surface of
ametocytes and gametes [18,19]. More recently, HAP2, a con-
erved male protein, located on the surface of the gamete plasma
embrane has demonstrated potent transmission-blocking efﬁ-
acy, in both the rodent malaria parasite Plasmodium berghei
20], and subsequently, the human malaria parasite P. falciparum
21].
Despite the large number of proteins that have been previ-
usly screened for the ability to initiate a transmission-blocking
esponse, the pool of parasite-derived TBV immunogens for which
ompelling evidence exists is disappointingly small. Only ﬁve
arasite-derived proteins are currently considered to be lead can-
idates, a number that is unacceptably small when considering the
uture development pipeline of TBVs. As a result, there is a real
eed to identify novel potential antigens to allow the formula-
ion of new potent TBVs in the future and to permit the potential
ombination of multiple immunogens in new anti-malarial vac-
ine formulations [22]. Two of the ﬁve currently proven, potent
ransmission-blocking immunogens are present on the surface of
he ookinete [23,24], whereas the other three have conformed
ocalization on the surface of the male gamete [18,19,25]. Previ-
us proteomic experimentation has resulted in the completion of
 proteome of the P. berghei male gamete, with subsequent in-
epth bioinformatics analysis [27]. Automated in silico analysis
or cellular location and function was carried out, using a raft of
7 individual prediction programmes [27], to generate consensus
redictions for each individual protein identiﬁed within the pro-
eome. From 624 proteins in total, 506 were successfully assigned putative cellular location/function, subject to experimental con-
rmation. Within this group, 23 molecules were classiﬁed as both
hypothetical” (i.e. with no detectable homologues or predictable
unction) and “putative surface molecules” (i.e. located within, or3 (2015) 437–445
associated with, the plasma membrane). Given these predicted
characteristics (novel and on the surface of male gametes), it is
logical to investigate the ability of these proteins to induce a
potent transmission-blocking response and potentially act as tar-
gets for novel TBVs. Amongst these proteins was the previously
identiﬁed parasite protein, Putative Secreted Ookinete Protein 12
(PSOP12/PBANKA 111340). PSOP12, like the lead TBV candidates
P48/45 and P230, is a putative member of the well-characterized
6-Cys family of proteins, of which 10 members have been charac-
terized [19], with a further 4 “6-Cys family associated” proteins
(including PSOP12) identiﬁed later [28]. Members of the family
are characterized by domains of approximately 120 amino acids in
size, containing six positionally conserved cysteines. Most mem-
bers of the family are expressed in a stage-speciﬁc manner stages
(gametocytes, sporozoites or merozoites) [19]. Five 6-Cys genes are
transcribed in gametocytes, and multiple studies [11–18] have suc-
cessfully demonstrated that the members of this protein family
play a role in the process of gamete recognition and fertiliza-
tion.
PSOP12 has been previously identiﬁed in a reverse genetics
screen and medium-throughput knockout study in P. berghei,  and
was demonstrated as expressed in the ookinete [29]. Expression
of the protein is predicted in both the P. berghei gametocyte and
ookinete [30]. A signal peptide is located at amino acids 1–24,
whereas our in depth bioinformatics consensus analysis [27], and
other recent studies [28] have predicted a potential single 6-Cys
domain at the C-terminal of the protein. The presence of a 6-
Cys domain in the PSOP12 protein is not predicted by “standard”,
commonly used bioinformatics analysis (e.g. BLASTP/PROSITE).
Multiple gene knockouts of psop12 have resulted in no detectable
phenotype in blood-, sexual-, liver or pre-erythrocytic stages, sug-
gesting that the protein could have a non-essential function within
the parasite lifecycle [29,RMgmDB]. The PSOP12 protein is encoded
by a 2.3 kb gene with a single 135 bp intron, located on chromo-
some 11, giving rise to a protein 712 amino acids in length with a
projected molecular weight of 85 kDa.
Here we describe the design and evaluation of a potential
TBV targeting P. berghei PSOP12 based on the baculovirus dual
expression system (BDES-PbPSOP12-spider), enabling expression
of antigens on the surface of viral particles and within infected
mammalian cells [31–33]. We  show that BDES-PbPSOP12-spider
elicits effective PSOP12 speciﬁc humoural immune responses
in mice, and confers signiﬁcant transmission-blocking activity,
assessed directly in vivo in the direct feeding assay (DFA), and ex
vivo in the standard membrane feeding assay (SMFA). We  demon-
strate, using serum obtained post-immunization, and by generation
of a transgenic GFP-reporter parasite, that PSOP12 is expressed
exclusively in gametocytes, gametes and ookinetes. Our data sug-
gests that PSOP12 in Plasmodium spp. could be a promising new
TBV target candidate.
2. Materials and methods
2.1. General parasite maintenance
General parasite maintenance was  carried out as described
in [34]. Brieﬂy, P. berghei ANKA 2.34 parasites were maintained
in 6–8 week old female Tuck Ordinary (TO) mice (Harlan) by
serial mechanical passage (up to a maximum of eight pas-
sages). If required, hyper-reticulosis was induced three days
before infection by treating mice with intraperitoneally (i.p.) with
200 l phenylhydrazinium chloride (PH; 6 mg/ml  in PBS; Pro-
Labo UK). Mice were infected i.p. and infections were monitored
using Giemsa-stained tail blood smears as described previously
[34].
cine 3
2
b
s
c
a
a
t
b
b
P
s
T
G
o
D
g
t
s
(
d
g
g
b
t
D
L
g
t
c
a
d
E
B
p
2
(
s
I
p
(
1
w
H
2
a
i
w
w
P
ﬁ
b
b
s
t
iK.A. Sala et al. / Vac
.2. Design and construction of recombinant baculovirus
To examine the ability of PbPSOP12 to initiate a transmission-
locking response, the recombinant baculovirus BDES-PbPSOP12-
pider (Fig. 1) was generated as follows. The DNA sequence
orresponding Ile294–Val721 of PbPSOP12 was  used to gener-
te BDES-PbPSOP12. To remove potential N-glycosylation sites,
sparagines at amino acids 337, 608 and 700 were substi-
uted with glutamine. The ﬁnal insert was  codon-optimized
oth for mammalian and AcNPV expression and synthesized
y GenScript Corp (Piscataway, NJ, USA). The codon-optimized
bPSOP12 gene was cloned into EcoRI/XmaI sites of pENTR-D-
PfCSP2-G2-sWPRE [35] to construct pENTR-D-sPb499-G2-sWPRE.
he baculovirus transfer vector, pFast-polh-EGFP-p10-hDAF-VSV-
2-Piggy-D-sPb499-G2-sWPRE(R), was generated by incubation
f pFast-polh-EGFP-p10-hDAF-VSV-G2-Piggy-RfA(R) and pENTR-
-sPb499-G2-sWPRE in the presence of LR Clonase (Invitro-
en Life Technologies) following the manufacturer’s instruc-
ions. The resulting pFast-polh-EGFP-p10-hDAF-VSV-G2-Piggy-D-
Pb499-G2-sWPRE(R) contained three gene cassettes encoding;
1) the PbPSOP12 gene under the control of the CMV-polyhedrin
ual promoter, (2) the human decay-accelerating factor (hDAF)
ene under the control of the p10 promoter, and (3) the egfp
ene under the control of the polyhedrin promoter. The recom-
inant bacmid was generated by Tn7-mediated transposition of
he gene cassettes in pFast-polh-EGFP-p10-hDAF-VSV-G2-Piggy-
-sPb499-G2-sWPRE(R) using the Bac-to-Bac system (Invitrogen
ife Technologies), according to manufacturer’s instructions. To
enerate BDES-PbPSOP12-spider, Sf9 cells were transfected with
he appropriate bacmids (2.0 g/well) or infected with infectious
ell culture supernatants. Cell culture supernatants were collected
nd budded virus titres were determined using a TCID50 end-point
ilution assay [40]. Virus infection was determined by monitoring
GFP expression with ﬂuorescence microscopy.
As a non-isotypic negative control, recombinant baculovirus
DES-GL3-spider harbouring the luciferase gene (from Photinus
yralis) under the control of the CMV  promoter was generated.
.3. Western blotting
Protein samples from puriﬁed BDES viral particles
2.5 × 106 pfu) were separated by 8 or 10% sodium dodecyl
ulfate-polyacrylamide gel electrophoresis, transferred to an
mmobilon-P transfer membrane (Merck Millipore), and then
robed either with anti-FLAG M2  mAb  with 1:2000 dilution
Sigma-Aldrich, Tokyo, Japan) or anti-CD55 (hDAF) mAb  with
:1000 dilution (Merck Millipore, Temecula, CA). Bound antibodies
ere subsequently detected by electrochemiluminescence (GE
ealthcare, Waukesha, WI)  as described previously [35].
.4. Immunization regime
BALB/c (inbred) mice (Harlan, UK) were immunized four times
t three-week intervals with 5 × 107 PFU of BDES-PbPSOP12-spider
ntramuscularly (i.m.). As a comparative negative control, mice
ere immunized with 5 × 107 PFU of BDES-GL3-spider i.m. Sera
ere collected prior to each injection/boost to evaluate anti-
bPSOP12 response. Final bleeds were taken two weeks after the
nal boost. Immunized mice were used to assess transmission-
locking responses by the direct feeding assay (DFA) as described
elow, following which, serum was collected by terminal anaesthe-
ia and cardiac puncture. Serum was subsequently used in the SMFA
o assess dose responsive transmission-blocking efﬁcacy, whilst
ndirect ﬂuorescent assay (IFA) was used to indicate the ability of3 (2015) 437–445 439
generated anti-BDES-PbPSOP12-spider polyclonal serum to recog-
nize the surface of the parasite.
2.5. Direct feeding assay (DFA)
Two  individual cohorts of mice (n = 5) were immunized i.m
with BEDS-PbPSOP12-spider or BDES-GL3-spider (negative con-
trol) as described above. Eight days following ﬁnal boost, all mice
were PH treated, and three days later infected with 106 iRBC
with P. berghei ANKA 2.34. Three days post-infection, pots of
starved An. stephensi mosquitoes (SDA 500 strain) were allowed
to feed on the anesthetized infected mice. >50 mosquitoes were
fed per mouse. Twenty four hours post-feed, mosquitoes were
brieﬂy anesthetized with CO2 and unfeds removed. Mosquitoes
were then maintained on 8% (w/v)) fructose, 0.05% (w/v) p-
aminobenzoic acid at 19–22 ◦C and 50–80% relative humidity.
Day 10 post-feeding, mosquito midguts were dissected and
oocyst intensity and prevalence recorded. Reduction in intensity
and prevalence in BEDS-PSOP12-spider immunized mice were
calculated with respect to the BEDS-GL3-spider immunized con-
trols.
2.6. Standard membrane feeding assay (SMFA)
An. stephensi (SDA 500 strain) were starved for 24 h and then
fed on heparanized P. berghei infected blood using standard mem-
brane feeding methods [34]. For each feed, 400 l of P. berghei 2.34
infected blood containing asexual and sexual stages of the parasite
was mixed with 200 l of PBS containing anti-BDES-PbPSOP12-
spider serum or anti-BEDS-GL3-spider serum (negative control) to
yield ﬁnal serum dilutions of 1:5, 1:10 and 1:50. Mosquitoes were
treated and maintained as described above.
2.7. Construction of transgenic PbPSOP12-GFP
To examine the expression and localization of PbPSOP12,
the PbPSOP12-GFP transgenic line was created, introducing
a C-terminal GFP tag to the native by single homologous
recombination. The targeting construct pPbPSOP12-GFP was
constructed using the backbone of the EGFP-tagging vec-
tor p277 [36]. The terminal 1351 bp of the psop12 gene
(PBANKA 111340) was  ampliﬁed by PCR, using the oligos PS1 (5′-
GGTACCGGATATTTCAAAAATCAGAGGATATTATATATCAATTATTTC-
3′) and PS2 (5-′GGGCCCAACGAATGTGTAGGTAATTTCGTATAGGATG-
3′), with ﬂanking KpnI and ApaI sites introduced (underlined) to
the amplicon. The resulting fragment was cloned in frame into the
ApaI/KpnI site of p277, resulting in pPbPSOP12-GFP. For transfec-
tion, this construct was linearized at a naturally occurring BclI site
within the psop12 sequence (Fig. 4A).
Parasites were transfected using the Nucleofector device
(Amaxa Biosystems) as described previously [36]. Inte-
gration of the DNA constructs into the chromosome was
conﬁrmed by PCR ﬂanking a region upstream from the
5′ integration site into the EGFP sequence (oligo PS3;
5′-GCAGGGAAAAATTCACCTTCTTCGTAAC-3; oligo PS4; 5′-
ACGCTGAACTTGTGGCCG-3′. Fig. 4 Panel B). Oligos against the
Pbs25 gene (PBANKA 0051500) were used as positive control (oli-
gos: 5′-CAACTTAGCATAAATATAATAATGCGAAAGTTACCGTGG-3′,
5′-CCATCTTTACAATCACATTTATAAATTCCATC-3′). GFP expression
in transfected, drug resistant parasites was conﬁrmed by ﬂuo-
rescence microscopy. Two  independent clones were obtained
from two independent transfections, demonstrating identical
phenotypes and GFP expression.
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Fig. 1. Design of BDES-PbPSOP12-spider. (A) Schematic representation of BDES-PbPSOP12-spider. BDES-PbPSOP12-spider consists of the gene cassette encoding amino
acids  Ile294 to Val721 of PbPSOP12 fused to the DNA sequence corresponding to Phe421–Arg511 of the VSV-G protein and the WPRE, and hDAF fused to VSV-G. SP = gp64
signal sequence. FLAG = FLAG epitope tag. Myc  = Myc  epitope tag. pCMVie = CMV  immediate early enhancer promoter. pPolh = polyhedron promoter. pp10 = p10 baculoviral
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.8. Immunoﬂuorescence assay (IFA)
To conﬁrm the expression of the PbPSOP12-GFP tagged fusion
rotein in our transgenic line, ﬂuorescent parasites were visual-
zed live. IFAs were also performed against multiple lifecycle stages
asexual parasites, gametocytes, gametes and ookinetes) using an
nti-GFP rabbit IgG at 1:200 dilution (Molecular Probes, A11122)
s primary antibody, and Alexa Fluor 488-labelled goat anti-rabbit
gG (Molecular Probes A11008) at 1:500 as the secondary antibody.
To assess the ability of our generated BEDS-PbPSOP12-spider
ntiserum to bind to the surface of the parasite, IFAs were
erformed against (wild-type) P. berghei 2.34 asexual parasites,
ametocytes, gametes and ookinetes using pooled anti-BEDS-
bPSOP12-spider polyclonal serum (harvested two  weeks post ﬁnal
leed) at 1:200 as primary antibody, and Alexa Fluor 488-labelled
oat anti-mouse IgG (Molecular Probes A11001) at 1:500 as the
econdary antibody. Anti-BEDS-GL3-spider polyclonal serum was
sed as the appropriate negative control. Ookinetes were cultured
s described in [37] and IFAs were performed as described previ-
usly [36].
.9. Ethical statement
All procedures were performed with accordance with the terms
f the UK Animals (Scientiﬁc Procedures) Act (PPL 70/7185) and
ere approved by the Imperial College Ethical Review Commit-
ee. The Ofﬁce of Laboratory Animal Welfare (OLAW) Assurance for
mperial College London covers all Public Health Service (PHS) sup-
orted activities involving live vertebrates in the US (no. A5634-01).
.10. Statistical analysis
Statistical analysis was performed with Graphpad Prism
oftware (Graphpad Software Inc.). For the DFA and SMFA, sig-
iﬁcant differences in oocyst intensity were assessed using the
ann–Whitney-U test (P < 0.05), whereas Fisher’s exact probability
est was used to assess differences in infection prevalence (P < 0.05).P12 and hDAF in puriﬁed viral particles was conﬁrmed by western blotting with
PSOP12-spider was  probed in lanes 1 and 3. BDES-GL3-spider (lanes 2 and 4) was
3. Results
3.1. Construction of baculovirus based PSOP12 vaccine
We  have previously developed a BDES-Pvs25-gp64 vaccine that
displays the transmission-blocking immunogen Pvs25 on the sur-
face of the viral envelope [31]. Immunization with this vaccine
induced strong humoural immune responses with high anti-Pvs25
titres and TB activity [31]. To further improve the utility of BDES
as a vaccine vector platform, the gene cassette encoding hDAF
fused to the C-terminal region of G protein of vesicular stom-
atitis virus (VSV-G) under the control of the p10 promoter was
introduced into the BDES. In addition, the gene cassette encoding
EGFP under the control of the polyhedrin promoter was intro-
duced to facilitate convenient virus titration. Using the resulting
BDES (named BDES-spider), BDES-PbPSOP12-spider, harbouring
the gene cassette encoding Ile294–Val721 of PbPSOP12 fused to VSV-
G and Woodchuck hepatitis virus post-transcriptional regulatory
element (WPRE) under the control of a dual promoter consisting
of the CMV-polyhedrin dual promoter was  constructed (Fig. 1A).
The C-terminal region of VSV-G comprises the ectodomain, and
the transmembrane and cytoplasmic domains of VSV-G, which
function to display foreign polypeptides on the baculovirus enve-
lope [31]. BDES-GL3-spider harbouring the luciferase gene under
the control of the CMV  promoter and the translational enhancer
element SP163 was  constructed to use as a negative control for
preceding experiments.
3.2. PbPSOP12-VSV-G fusion protein expression on baculoviral
particles
To examine the expression of recombinant PbPSOP12 on the
surface of the viral envelope, BDES-PbPSOP12-spider viral particles
were puriﬁed and analysed by western blotting using an anti-FLAG
mAb, which recognizes a linear epitope within the N-terminal tag
of the construct (Fig. 1B). A single band with relative molecu-
lar mass (Mr) of 65 kDa was observed in BDES-PbPSOP12-spider,
K.A. Sala et al. / Vaccine 33 (2015) 437–445 441
Fig. 2. Assessment of in vivo transmission-blocking TB efﬁcacy by DFA in immunized mice. Two  groups of ﬁve mice were immunized with either BDES-PbPSOP12-spider
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ata  points represent the number of oocysts found in individual mosquitoes 12 days
.E.M.  within individual samples.
orresponding to the predicted Mr  64.8 kDa of the PbPSOP12-VSV-
 fusion protein (lane 1). No corresponding band was seen in
DES-GL3-spider (lane 2) because of lack of the FLAG epitope tag
ene.
Baculovirus vector is inactivated by human complement in vivo
46], which is a potent primary barrier to in vivo application of
aculovirus vectors. To protect BDES against the complement-
ediated inactivation, hDAF was used to shield viral envelope. To
onﬁrm expression, a western blot was performed against puriﬁed
iral particles using an anti-DAF mAb. A triplet band with Mr 55, 49
nd 43 kDa was observed in BDES-PbPSOP12-spider (lane 3), which
ay  be due to post-translational modiﬁcation. No band was  seen
n BDES-GL3-spider because of lack of the hDAF gene (lane 4).
.3. Immunization with BDES-PbPSOP12 induces
bPSOP12-speciﬁc antibody responses
To conﬁrm the induction of PbPSOP12-speciﬁc antibodies to
ative protein on the surface of the sexual stages of the parasite
y immunization with BDES-PbPSOP12-spider, we performed IFA
n WT  P. berghei 2.34, using pooled serum generated from mice
mmunized with BDES-PbPSOP12-spider. Surface staining on male
nd female gametes and ookinetes was observed (Fig. 4B), con-
rming the ability of our generated serum to recognize native
bPSOP12 on the surface of the sexual/ookinete stages of the para-
ite. Staining was not observed in non-permeablized gametocytes,
uggesting a lack of surface localization in non-activated RBCs.
nti-BEDS-GL3-spider polyclonal serum, used as negative control,
esulted in no detectable staining in the blood stage, or sexual
tages of the parasite whether live or ﬁxed, or permeablized or
on-permeablized.
.4. Evaluation of in vivo transmission-blocking activity (DFA)For examination of transmission-blockade in vivo, mice were
nfected with P. berghei ANKA 2.34, following which An. stephensi
osquitoes were allowed to feed directly on the immunized
nd challenged hosts (Fig. 2, Table 1) three days-post infection.ion of transmission blockade was performed by direct gametocyte feed. Individual
feed. Horizontal bars indicate mean intensity of infection, whilst error bars indicate
Mosquitoes that fed on the 5 control mice displayed an average
intensity of 76.2 oocysts/midgut, whereas following i.m. immu-
nization with BDES-PbPSOP12-spider, mean intensity was reduced
to 35.7 oocysts/midgut, a reduction (P < 0.005) of 53.1%. Corre-
spondingly, mean infection prevalence was  reduced from 94.1% to
83.8%, a modest, but signiﬁcant reduction (P < 0.005).
3.5. Evaluation of in vitro transmission-blocking activity (SMFA)
Following i.m. immunization with BDES-PbPSOP12-spider,
pooled serum harvested from mice (16 days after ﬁnal boost) pro-
foundly reduced the intensity and prevalence of oocyst infection
on the mosquito midgut in comparison with BDES-GL3-spider iso-
typic control serum (Fig. 3, Table 2). Inhibition was dose dependent.
Immune serum, diluted 1:5, inhibited parasite intensity by 76.4%
and reduced prevalence by 47.2%. At a dilution of 1 in 10, inten-
sity was  reduced by 53.9% and prevalence by 18.9%. Conversely,
at the lowest dilution tested (1 in 50), the presence of serum
resulted in no signiﬁcant transmission-blocking effect, with a small
non-signiﬁcant increase (5.5%) in infection prevalence recorded.
In contrast to anti-BDES-PbPSOP12-spider serum, the presence
of anti-BDES-GL3-spider sera resulted in parasite intensities and
prevalence of infection that were not signiﬁcantly different from
each other, irrespective of dilution.
3.6. Expression and localization of PbPSOP12
To additionally examine the localization of PbPSOP12 on the
sexual stages of the parasite, and ascertain its accessibility to attack
by antibodies induced by the host immune system, we utilized
targeted-single homologous recombination to generate a trans-
genic P. berghei parasite, expressing the endogenous PbPSOP12
protein with a C-terminal EGFP fusion tag (Fig. 4A). Successful
integration following drug selection was conﬁrmed by PCR using
the speciﬁc primers PS3 and PS4, giving rise to a single band of
1619 kb (comprising of 143 bp of the upstream region, 1359 bp of
the psop12 locus and 117 bp of the egfp ORF), spanning a region
upstream from the psop12 locus, the recombination site within the
442 K.A. Sala et al. / Vaccine 3
Fig. 3. Determination of in vitro transmission-blocking efﬁcacy of anti-P.
berghei PbPSOP12 serum using the SMFA. P. berghei WT 2.34 infected blood was
mixed with anti-PbPSOP12-spider mouse sera or mouse BEDS-GL3-spider sera (neg-
ative control) at ﬁnal dilutions of 1 in 5, 1 in 10 and 1 in 50. Individual data points
represent the number of oocysts found in individual mosquitoes 12 days post feed.
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lab-based “bottle” studies have demonstrated that anti-malarial
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d
aorizontal bars indicate mean intensity of infection, whilst error bars indicate S.E.M.
ithin individual samples.
ene itself, and the region encoding gfp (Fig. 4C). The C-terminal
GFP tag caused no obvious growth defect in blood or sexual
tages, and did not interfere with parasite transmission through
n. stephensi mosquitoes. Live ﬂuorescence microscopy showed
able 1
n vivo evaluation of transmission-blocking effect of BEDS-PbPSOP12-spider. Changes in i
f  mice immunized with BEDS-PbPSOP12-spider were calculated with respect to the app
GL3: M1 GL3: M2 GL3: M3 GL3: M4 GL3: M5
No. mosquitoes 43 50 50 50 30 
No.  infected 40 45 50 47 28 
No.  non-infected 3 5 0 3 2 
Infection prevalence (%) 93 90 100 94 93 
Oocyst Intensity 94.5 41.1 96.7 68.3 79.8 
S.E.M  11.3 3.9 8.4 8.3 12.2 
Mean  prevalence (%) 94.1 
Mean intensity 76.2 
Inhibition in prevalence – 
Inhibition in intensity (%) – 
a P < 0.05, Fisher’s exact test.
b P < 0.05, Mann–Whitney U test.
able 2
valuation of transmission-blocking effect of anti-P. berghei PSOP12 serum by SMF
ilution of BEDS-derived anti-PbPSOP12 mouse sera at 1 in 5, 1 in 10 and 1 in 50 were cal
t  the relevant concentration.
GL3: 1:5 PSOP12: 1:5 GL
No. mosquitoes 50 45 50
No.  infected 40 19 33
No.  non-infected 10 26 17
Infection prevalence (%) 80 42 66
Oocyst intensity 18.1 4.3 15
S.E.M  2.8 1.4 2
Inhibition in prevalence (%) 47.2a 18
Inhibition in intensity (%) 76.4b 53
a P < 0.05, Fisher’s exact test.
b P < 0.05, Mann–Whitney U test.3 (2015) 437–445
PbPSOP12-EGFP staining in micro- and macrogametocytes, acti-
vated male and female gametes, and ookinetes (Fig. 4B). Staining
was not observed in the blood stages of the parasite lifecycle or
in later mosquito stages. This staining pattern was  observed in
all transgenic parasites examined over three independent exper-
iments by ﬂuorescence microscopy following drug selection with
pyrimethamine. In all stages where expression was observed much
of the ﬂuorescence signal emanated from the cell periphery, sug-
gesting localization to the plasmalemma, as predicted previously in
silico [27]. This was  further conﬁrmed by IFA on ﬁxed parasites per-
formed with anti-EGFP mAb  under non-permeablizing conditions,
which demonstrated surface staining in the gametes and ookinetes.
Identical surface staining was noted in transgenic PbPSOP12-EGFP
parasites, and in WT  P. berghei parasites stained with anti-BDES-
PbPSOP12-spider serum, conﬁrming the localization of PbPSOP12
on the surface of the sexual/ookinete stages of the parasite, whilst
suggesting that the presence of the EGFP-fusion protein in the
transgenic line does not alter the native localization of the protein.
Staining in the zygote was not observed.
4. Discussion
Transmission-blocking vaccines aim to reduce the burden of
malaria by preventing transmission of Plasmodium from humans,
carrying the sexually active forms of the parasite within their
peripheral blood, to mosquitoes. By targeting molecules on the
parasite surface, it is possible to kill parasites or disrupt their
development within the anopheline vector, preventing onwards
transmission. Previous studies on multiple antigens (most notably
P25, P28, P48/45, P230 and HAP2) have consistently demonstrated
the utility of this approach to malarial control. Furthermore, recenttransmission-blocking interventions can be capable of eliminating
Plasmodium from vertebrates in the absence of other interven-
tions [39]. Despite numerous studies investigating the utility of a
ntensity (arithmetic mean number of oocyts per midgut) and prevalence in groups
ropriate, grouped BEDS-GL3-spider immunized mice.
 PSOP12: M1 PSOP12: M2  PSOP12: M3  PSOP12: M4  PSOP12: M5
25 55 50 33 28
21 50 45 25 22
4 5 5 8 6
84 91 90 75.8 78.6
38.5 29.5 46.8 26.3 34.6
7.0 3.3 5.4 4.9 5.4
83.8
35.7
10.9a
53.1b
A. Change in intensity (mean number of oocyts per midgut) and prevalence with
culated with respect to appropriate serum derived from BEDS-GL3-spider controls
3: 1:10 PSOP12: 1:10 GL3: 1:50 PSOP12: 1:50
 50 50 50
 27 36 38
 23 14 12
 54 72 76
.7 7.24 13.4 12.5
.7 1.9 2.4 2.3
.9 −5.5
.9b 6.7
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Fig. 4. GFP tagging of the endogenous psop12 locus, and localization in the sexual stages of P. berghei. (A) Schematic showing the psop12 locus, the targeting vector
pPbSOP12-GFP, and the insertion of an egfp sequence in-frame within the endogenous locus. (B). Fluorescence micrographs of live parasites expressing PbPSOP12-GFP, or
ﬁxed,  non-permablized parasites probed with anti-BDES-PbPSOP12-spider serum. Each panel shows an overlay of GFP ﬂuorescence (green) and DNA labelled with Hoechst
(blue).  White scale bars indicate 10 m.  IFA with anti-BDES-GL3-spider (control) serum resulted in no observable staining. (C) PCR conﬁrmation of integration of egfp into
the  psop12 locus. Oligonucleotides PS3 and PS4 were used to detect integration, pbs25 oligos were used as positive controls. P. berghei WT 2.34 gDNA was used as a negative
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umber of TBV antigens over the last 40 years, there is a currently a
eal need for new potential TBV vaccine candidates to support the
ontinuing development pipeline [4].
This study describes the evaluation of serum antibodies
aised against baculovirus-expressed PbPSOP12 as a transmission-
locking agent. The biological signiﬁcance or function of PbPSOP12
till remains to be elucidated. Multiple gene knockouts [29,RMg-
DB] of the psop12 locus resulted in no detectable phenotype,
ndicating a non-essential role within the parasite lifecycle. Both
n silico predictions [27,29,30], and the localization carried out
ithin this study indicate that PbPSOP12 is located on the sur-
ace of the sexual stages of the parasite (namely the male and
emale gametes, and ookinetes), and as such is accessible for
ntibody-mediated attack as part of a transmission-blocking strat-
gy. This criteria is logically vital for the ability of an antigen
o induce a transmission-blocking response and the experimen-
ation described here illustrates that surface localization should
e considered a vital marker to assess if a polypeptide should beconsidered a putative TBV target. Screens for novel vaccine candi-
dates based on knock-outs or phenotypic analysis (e.g. [29]) can
undoubtedly yield interesting and valuable information regard-
ing cell biology, but surface localization on the sexual stages of
the target should be considered a key parameter for the triage
and selection of novel transmission-blocking candidates. As fur-
ther demonstration of this concept, the current lead TBV antigen,
P25 is currently considered to be “non-essential”, and its knockout
results in no detectable phenotype (RMgmDB).
An additional essential attribute for the selection of new
TBV antigens is the ability to induce a strong immune response
following immunization with the appropriate recombinant pro-
tein/immunogen. Within the scope of this study we  achieve
this by utilizing the baculovirus dual expression system [31].
We demonstrate that sera harvested from mice immunized with
BDES-PbPSOP12-spider is capable of speciﬁcally recognizing native
PbPSOP12 on the surface of the sexual stages of the parasite, indi-
cating the potential utility of BDES-PbPSOP12 as an efﬁcacious TBV,
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nd the ability of the BDES system to express vaccine candidates,
ven those with 6-Cys domains.
Numerous protein expression/adjuvant/delivery systems have
een tested over previous years for their ability to induce TB
esponses with varying success. Speciﬁcally, when dealing with
lasmodial proteins, the A + T rich nature of the genome [42]
an lead to difﬁculties in producing recombinant protein con-
aining such native epitopes (48/45). “Standard” immunization
egimes, using recombinant protein, either alone or in combina-
ion with adjuvants (e.g. Freund’s, aluminium hydroxide, cholera
oxin (CT) [40,41]) all indicate that immunized proteins requires
inear or conformation dependent epitopes, and a strong adjuvant
o induce transmission-blocking antibodies. Use of commonly uti-
ized adjuvants to initiate potent immune responses can often have
ndesirable side effects and questionable safety proﬁles (CT) [43].
n contrast to this, the BDES circumvents standard protein expres-
ion issues by initiating viral expression of polypeptides, and has
een successfully used to initiate immune responses and induce
ransmission-blocking activity against a wide range of Plasmodium
roteins in the past [31–33,35]. It may  additionally offer an attrac-
ive immunization method as it exhibits low cytotoxicity and is
ncapable of replication in mammalian cells. [31]. The value of using
 system similar to this in a suitable small-scale animal model for
he in vivo assessment of vaccine-induced transmission-blocking
unctional responses is demonstrated by this study. Put simply,
t is much cheaper, easier, and ethically less problematic to iden-
ify and triage new anti-malarial vaccine candidates in a rodent
alarial model before proceeding to validation in expensive and
thically complex human clinical trials. By combining the conve-
ient baculovirus dual expression system with the highly tractable
37] P. berghei model, we have a powerful tool to identify, triage
nd examine new potential TBV candidates, with the possibility
f adding comparatively simple analysis of cell biology in rodent
alaria parasites if desired. Despite this undoubted application in
nimal models, the use of baculoviral delivery systems still requires
alidation in human trials. A recently published study has demon-
trated that baculovirus dual expression based vaccines are safe and
ell tolerated, with acceptable reactogenicity and systemic toxic-
ty in a primate model [35]. It would be advantageous to perform
imilar studies in the future to examine fully the possibility of offer-
ng an alternative to current vaccine delivery platforms for clinical
rials.
Within the scope of this study, the BDES-PbPSOP12-spider vac-
ine initiated modest, yet signiﬁcant, transmission blockade in vivo
ollowing active immunization (53.1% reduction in intensity, 10.9%
eduction in prevalence). Higher transmission blockade was  seen
ith in vitro experimentation in the SMFA (up to a 76.4% reduc-
ion in intensity and a 47.2% reduction in prevalence). It remains
o be seen if increased transmission blocking potency could be
nitiated using this antigen with different baculoviral expression
onstructs, delivery systems based on other viral vectors (e.g.
denovirus [44]) or standard recombinant protein/adjuvant immu-
ization methods [21]. PSOP12 is the third member of the 6-Cys
rotein family, with P48/45 and P230, to demonstrate the ability
o initiate an anti-malarial transmission blocking response. There
re currently 14 putative members of the 6-Cys family identiﬁed
n Plasmodium, with 10 initially identiﬁed [19], and a further 4
haracterized following in-depth structural studies [28,45]. Fam-
ly members are often located on the parasite surface, suggesting a
unction in cell-cell interactions (e.g. the 6-Cys proteins P52, P36,
equestin and B9 play vital roles related to infection of the liver
y the parasite [28]). Five family members have previously been
haracterized as expressed in the sexual stages of the parasite,
nd three of the proteins that are expressed in the gamete function
n the recognition and adhesion between male and female gametes
19]. This study supports previous in-depth studies highlighting the
[3 (2015) 437–445
potential of members of the 6-Cys to act as TBV vaccine candidates,
and suggests that continued analysis of family members could be
advantageous.
5. Conclusions
In this study we design, construct and evaluate a novel TBV
targeting the 6-Cys protein family member PSOP12 in P. berghei.
Expression of the protein in the baculovirus dual expression sys-
tem, followed by immunization of mice induces speciﬁc humoural
immune response. The resulting serum recognizes the surface of
the sexual and ookinete stages of the parasite in a manner consis-
tent with observed expression of the PSOP12 protein. A range of TB
assays demonstrate signiﬁcant TB efﬁcacy both in vivo and in vitro
using the sera raised. As such, our data indicates that PSOP12 in
Plasmodium spp. could be a promising new TBV target candidate,
and that further experimentation to examine the protein within
human malaria parasites could be advantageous.
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